Inventor · disambiguated record
Christoph Wolfgang Zapf
Also filed as: ZAPF CHRISTOPH W · ZAPF CHRISTOPH WOLFGANG
23 granted patents·16 pending applications·158 citations·filing 2013–2025
95Inventor score
Files withPFIZER18NURIX THERAPEUTICS INC11CYSTIC FIBROSIS FOUND5CYSTIC FIBROSIS FOUND THERAPEUTICS INC4CELGENE CORP1
Top patents by PatentIndex Score
39 records- 0197US11702424B2Bicyclic-fused heteroaryl or aryl compoundsPFIZER·Filed 2020·Granted Jul 18, 2023·4 cites·8 claims
- 0297US11530229B2Cyano cyclobutyl compounds for CBL-B inhibition and uses thereofNURIX THERAPEUTICS INC·Filed 2020·Granted Dec 20, 2022·12 cites·71 claims
- 0397US11464802B23-substituted piperidine compounds for Cbl-b inhibition, and use thereofNURIX THERAPEUTICS INC·Filed 2020·Granted Oct 11, 2022·14 cites·53 claims
- 0497US11401267B2Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereofNURIX THERAPEUTICS INC·Filed 2020·Granted Aug 2, 2022·11 cites·32 claims
- 0596US10208053B2Bicyclic heteroaryl derivatives as CFTR potentiatorsCYSTIC FIBROSIS FOUND THERAPEUTICS INC·Filed 2018·Granted Feb 19, 2019·31 cites·19 claims
- 0695US10131670B2Bicyclic heteroaryl derivatives as CFTR potentiatorsCYSTIC FIBROSIS FOUND THERAPEUTICS INC·Filed 2017·Granted Nov 20, 2018·27 cites·8 claims
- 0795US9879022B2Bicyclic-fused heteroaryl or aryl compoundsPFIZER·Filed 2016·Granted Jan 30, 2018·19 cites·22 claims
- 0895US9458168B2Bicyclic-fused heteroaryl or aryl compoundsPFIZER·Filed 2015·Granted Oct 4, 2016·17 cites·44 claims
- 0994US11951133B23-substituted piperidine compounds for Cbl-b inhibition, and use thereofNURIX THERAPEUTICS INC·Filed 2022·Granted Apr 9, 2024·2 cites·36 claims
- 1092US12485144B23-substituted piperidine compounds for Cbl-b inhibition, and use thereofNURIX THERAPEUTICS INC·Filed 2024·Granted Dec 2, 2025·1 cites·40 claims
- 1192US12049471B2Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereofNURIX THERAPEUTICS INC·Filed 2022·Granted Jul 30, 2024·1 cites·16 claims
- 1291US10793579B2Bicyclic-fused heteroaryl or aryl compoundsPFIZER·Filed 2019·Granted Oct 6, 2020·3 cites·8 claims
- 1390US12234230B2Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereofNURIX THERAPEUTICS INC·Filed 2022·Granted Feb 25, 2025·1 cites·5 claims
- 1486US10329302B2Bicyclic-fused heteroaryl or aryl compoundsPFIZER·Filed 2018·Granted Jun 25, 2019·3 cites·2 claims
- 1585US12202836B2Bicyclic-fused heteroaryl or aryl compoundsPFIZER·Filed 2023·Granted Jan 21, 2025·0 cites·14 claims
- 1685US10174000B2Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulatorsPFIZER·Filed 2016·Granted Jan 8, 2019·5 cites·10 claims
- 1783US10301315B2Pyrrolopyrimidines as CFTR potentiatorsCYSTIC FIBROSIS FOUND THERAPEUTICS INC·Filed 2017·Granted May 28, 2019·1 cites·20 claims
- 1881US10494374B2Pyrrolopyrimidines as CFTR potentiatorsCYSTIC FIBROSIS FOUND·Filed 2019·Granted Dec 3, 2019·1 cites·67 claims
- 1981US10266513B2Bruton's tyrosine kinase inhibitorsPFIZER·Filed 2017·Granted Apr 23, 2019·2 cites·6 claims
- 2081US2025136590A1Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereofNURIX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2180US2024409555A1Cyano cyclobutyl compounds for cbl-b inhibition and uses thereofNURIX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2279US10377762B2Bicyclic heteroaryl derivatives as CFTR potentiatorsCYSTIC FIBROSIS FOUND THERAPEUTICS INC·Filed 2018·Granted Aug 13, 2019·1 cites·15 claims
- 2379US10316018B2Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulatorsPFIZER·Filed 2018·Granted Jun 11, 2019·2 cites·4 claims
- 2477US2023250100A1Pyrrolopyrimidines as CFTR PotentiatorsCYSTIC FIBROSIS FOUND·Filed 2023·Application pending·0 cites
- 2572US2020017512A1Pyrrolopyrimidines as cftr potentiatorsCYSTIC FIBROSIS FOUND·Filed 2019·Application pending·0 cites
- 2669US2021171534A1Pyrrolopyrimidines as CFTR PotentiatorsCYSTIC FIBROSIS FOUND·Filed 2021·Application pending·0 cites
- 2768US2021002251A1Bruton's Tyrosine Kinase InhibitorsPFIZER·Filed 2020·Application pending·0 cites
- 2867US2020039960A1Rorc2 inhibitors and methods of use thereofPFIZER·Filed 2019·Application pending·0 cites
- 2966US10815213B2Bruton's tyrosine kinase inhibitorsPFIZER·Filed 2019·Granted Oct 27, 2020·0 cites·4 claims
- 3065US10766904B2Bicyclic heteroaryl derivatives as CFTR potentiatorsCYSTIC FIBROSIS FOUND·Filed 2019·Granted Sep 8, 2020·0 cites·1 claims
- 3165US2019144429A1Rorc2 inhibitors and methods of use thereofPFIZER·Filed 2019·Application pending·0 cites
- 3263US2016046597A1Rorc2 inhibitors and methods of use thereofPFIZER·Filed 2014·Application pending·0 cites
- 3363US2018282304A1Rorc2 inhibitors and methods of use thereofPFIZER·Filed 2018·Application pending·0 cites
- 3462US2018086736A1Rorc2 inhibitors and methods of use thereofPFIZER·Filed 2017·Application pending·0 cites
- 3560US2017233371A1Rorc2 inhibitors and methods of use thereofPFIZER·Filed 2017·Application pending·0 cites
- 3659US2015291554A1Bruton's Tyrosine Kinase InhibitorsPFIZER·Filed 2013·Application pending·0 cites
- 3751US2022387395A1Urea, amide, and substituted heteroaryl compounds for cbl-b inhibitionNURIX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3851US2025368620A1ARNT Degrading Compounds and Uses ThereofCELGENE CORP·Filed 2025·Application pending·0 cites
- 3950US2022324835A1Inhibitors of cbl-b and methods of use thereofNURIX THERAPEUTICS INC·Filed 2019·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →